Retatrutide and Heart Rate: Increases, Risks, and What to Watch

Retatrutide raises resting heart rate by a modest amount, roughly 6 to 7 beats per minute at the highest doses in its phase 2 trial, with smaller increases at lower doses. The rise tends to peak around week 24 and then ease over the following months. This is consistent with the broader class of incretin medicines, which lift resting pulse by a few beats per minute. For most people the change is small and clinically quiet, but it is real, dose related, and worth understanding before you start.

Retatrutide is investigational. As of June 2026 it is not approved by the FDA or any major regulator and is being studied in phase 3 trials. Everything below comes from phase 2 data and from what is known about closely related drugs, not from a finished cardiovascular outcomes study.

How much does retatrutide raise heart rate?

In the phase 2 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2023), 338 adults with obesity received weekly retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, over 48 weeks. The trial measured heart rate as part of routine safety monitoring.

Key findings on pulse:

• Resting heart rate increased in a dose dependent way, meaning higher doses produced larger increases.
• The largest average rise was in the range of roughly 6 to 7 beats per minute on the 8 mg and 12 mg arms.
• The increase peaked at about week 24 and then declined over weeks 36 to 48, rather than climbing indefinitely.
• The pattern resembled what is seen with other incretin therapies, where pulse rises early and partially settles with continued treatment.

To put that in context, GLP-1 receptor agonists as a class raise resting heart rate by an average of about 2.4 beats per minute, with a reported range from roughly 0.1 to 5.7 beats per minute across agents. Retatrutide sits at the higher end of that spread at its top doses, which is expected given its potency and its added glucagon activity.

These figures describe group averages. Your individual response can be larger or smaller, and a few beats per minute on a chart can feel different from how your body actually responds day to day.

Why incretin drugs raise heart rate

The heart rate effect is not a side reaction or an impurity issue. It comes from how these drugs work. Research on GLP-1 shows a direct chronotropic effect on the heart, meaning GLP-1 speeds the natural pacemaker.

What the mechanism studies found:

• GLP-1 receptors are present on the pacemaker cells of the sinus node, the heart's natural rhythm generator.
• When GLP-1 activates those receptors, the sinus node fires faster, raising heart rate.
• This effect persisted in isolated hearts with no nerve connections, which means it does not depend on the autonomic nervous system or on stress hormones.
• The cellular signal involves changes in calcium cycling inside the pacemaker cells.
• Blocking the GLP-1 receptor abolished the effect, confirming the receptor is responsible.

In short, the medicine talks to the heart's pacemaker directly. That is why beta blockers, which work through the nervous system, do not fully cancel the effect in lab models.

If you want the broader picture of how retatrutide engages its three targets, see our retatrutide mechanism of action guide and the overview of what retatrutide is.

The glucagon component and why retatrutide is different

Retatrutide is a triple agonist. It activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. That third target sets it apart from semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP).

Glucagon matters here because glucagon itself has positive chronotropic and inotropic properties, meaning it can speed the heart and increase contraction force. Glucagon has even been used clinically as a rescue treatment for beta blocker overdose precisely because it raises heart rate independent of adrenaline pathways.

So retatrutide may push heart rate through two overlapping routes:

• The GLP-1 pathway shared with the rest of the class.
• An additional glucagon driven effect unique to glucagon containing agonists.

It is reasonable to expect retatrutide to land at or above the top of the class for heart rate, and the phase 2 numbers fit that expectation. That said, a direct, dose matched comparison isolating the glucagon contribution in humans has not been published, so treat the two pathway model as a well grounded hypothesis rather than a settled fact. You can compare the molecules side by side in retatrutide vs tirzepatide and retatrutide vs semaglutide.

Does a higher heart rate mean retatrutide is bad for the heart?

Not necessarily, and the distinction matters. A modest rise in resting pulse is a known feature of incretin drugs, yet the GLP-1 class as a whole has shown cardiovascular benefit in large outcome trials of approved agents. A few extra beats per minute did not erase those benefits.

For retatrutide specifically, the phase 2 data were reassuring but limited:

• The rate of serious adverse events was about 4 percent in both the retatrutide and placebo groups.
• No increase in heart attacks, strokes, or major adverse cardiovascular events was reported with retatrutide during the trial and follow up.
• Most side effects were gastrointestinal (nausea, diarrhea, vomiting) and were mild to moderate, concentrated during dose escalation.

The important caveat: phase 2 trials are small and short. With 338 people over 48 weeks, the obesity study was not designed or powered to detect rare cardiac events or long term outcomes. The real answer on cardiovascular safety will come from the dedicated cardiovascular outcomes trial, TRIUMPH-Outcomes (NCT06383390), which is testing retatrutide against placebo in adults with obesity who also have established cardiovascular or kidney disease. Until that reads out, long term effects on heart attack, stroke, and cardiovascular death remain unknown.

For a fuller safety picture, see is retatrutide safe and the retatrutide side effects breakdown.

When a faster heart rate is worth watching

A few extra beats per minute at rest is usually not dangerous on its own. The concern is when heart rate climbs higher than expected, persists, or comes with symptoms. Pay attention to the difference between a quiet number on a fitness tracker and how you actually feel.

Talk to a clinician promptly if you notice:

• A sustained resting heart rate above roughly 100 beats per minute (tachycardia) that does not settle.
• Palpitations, a pounding or fluttering chest, or a sense of skipped beats.
• Chest pain or pressure, especially with exertion.
• Shortness of breath, lightheadedness, or fainting.
• A heart rate jump that feels far larger than a few beats per minute.

Some situations call for extra caution and a conversation with your prescriber before starting or escalating:

• Existing arrhythmias such as atrial fibrillation.
• A history of heart failure or coronary disease.
• Resting tachycardia at baseline.
• Other medicines or stimulants that also raise heart rate.

Seek emergency care for chest pain with sweating or nausea, fainting, or a very fast irregular heartbeat. These are not expected effects of the drug and need urgent evaluation.

Managing heart rate on retatrutide

Most heart rate increases are handled with monitoring and a sensible titration plan rather than stopping the drug. Practical steps:

• Titrate slowly. Heart rate effects track with dose, so following a gradual escalation schedule gives your body time to adjust. See the retatrutide dosage guide and dosing schedule.
• Measure at rest. Check your pulse in the morning before coffee or activity for a consistent baseline, and note the trend over weeks rather than reacting to a single high reading.
• Stay hydrated. Dehydration from nausea or reduced intake can raise heart rate on its own.
• Limit added stimulants. Excess caffeine or stimulant supplements stack on top of the drug's effect.
• Review your other medicines. Tell your prescriber about everything you take, including over the counter products.
• Do not self dose. Compounded or research grade product without medical oversight removes the monitoring that makes a faster pulse manageable. See compounded retatrutide.

Because the trial increase peaked near week 24 and then eased, an early bump in pulse does not automatically predict where you will settle. Tracking the trend matters more than any single day.

FAQ

How many beats per minute does retatrutide raise heart rate?

In phase 2 trials the average increase was roughly 6 to 7 beats per minute at the highest doses (8 mg and 12 mg), with smaller rises at lower doses. The class average for GLP-1 drugs is about 2.4 beats per minute. Individual responses vary.

Does the heart rate increase go away over time?

In the phase 2 obesity trial the rise peaked around week 24 and then declined through weeks 36 to 48, so it eased rather than worsening with continued use. It does not fully disappear for everyone, and the trend is what to watch.

Is retatrutide safe for people with heart conditions?

There is no clear answer yet because retatrutide is investigational and its cardiovascular outcomes trial is still running. People with arrhythmias, heart failure, or coronary disease should only consider it under direct medical supervision, and trials have typically excluded those with significant cardiovascular disease.

Why does retatrutide raise heart rate more than semaglutide?

Retatrutide adds glucagon receptor activity on top of GLP-1 and GIP. Glucagon has heart rate raising properties of its own, which likely adds to the GLP-1 effect shared across the class. Its high potency also contributes.

Should I stop retatrutide if my heart rate goes up?

A few extra beats per minute is usually expected and not a reason to stop. A sustained resting rate above about 100, palpitations, chest pain, or fainting do warrant contacting a clinician promptly. Do not start or stop a prescription medicine based on this article.

The bottom line

Retatrutide raises resting heart rate by a modest, dose dependent amount, about 6 to 7 beats per minute at the top doses in phase 2, peaking near week 24 before easing. The effect is driven by direct action on the heart's pacemaker, with an extra push likely from the glucagon component that makes retatrutide unique. Phase 2 safety signals were reassuring but short term, and the definitive cardiovascular verdict awaits the ongoing outcomes trial. Track your pulse, titrate slowly, and flag any sustained tachycardia or chest symptoms to a clinician.

To go deeper, see retatrutide clinical trial results, the retatrutide dosage chart, and when retatrutide will be available.

This article is for informational purposes only and is not medical advice. Retatrutide is investigational and not approved for use. Consult a qualified clinician about your individual situation.